Faeth Therapeutics, Inc. (FTH) Stock Price & Analysis
Faeth Therapeutics, Inc. (FTH) rose 1.91% to USD 28.29 as of July 25, 2026 at 05:22 UTC, according to Nexqual real-time market data.
FTH last closed at USD 27.76; the session ranged USD 27.03–28.29 on volume of 129,087 shares. Market capitalization is $729.28M, with a 52-week range of USD 6.33–37.9 (NCM). Source: Nexqual, July 25, 2026 at 05:22 UTC.
Key Statistics (as of July 25, 2026 at 05:22 UTC)
| Price | USD 28.29 |
|---|---|
| Change | ▲ 1.91% (up) |
| Previous Close | USD 27.76 |
| Open | USD 27.5 |
| Day Range | USD 27.03 – 28.29 |
| 52-Week Range | USD 6.33 – 37.9 |
| Volume | 129,087 shares |
| Market Cap | $729.28M |
| Exchange | NCM |
Technical Analysis (FTH)
Nexqual's technical model rates FTH "STRONG BUY" based on 5 bullish and 0 bearish signals across 125 daily candles, as of July 25, 2026 at 05:22 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 57.75 (neutral) |
| vs SMA50 | Above (USD 21.64) |
| MACD | 1.86 (positive) |
Analyst Ratings (FTH)
Wall Street analysts rate FTH "Strong Buy" based on 7 analysts, with a mean price target of USD 54 (range USD 50–60), per Nexqual as of July 25, 2026 at 05:22 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 7 |
| Mean Target | USD 54 |
| High Target | USD 60 |
| Low Target | USD 50 |
| Buy / Hold / Sell | 8 / 0 / 0 |
Earnings (FTH)
| Revenue Estimate | $0 |
|---|
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -131.45 vs est -0.62 ▼ miss |
| 2025-12-31 | USD -3.74 vs est -4.81 ▲ beat |
| 2025-09-30 | USD -3.62 vs est -4.11 ▲ beat |
| 2025-06-30 | USD -3.91 vs est -5 ▲ beat |
Source: Nexqual, July 25, 2026 at 05:22 UTC.
Financials & Fundamentals (FTH)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Current Ratio | 14.39 |
| Total Cash | $202.79M |
| Total Debt | $1.04M |
| Free Cash Flow | $-92.24M |
Source: Nexqual, July 25, 2026 at 05:22 UTC.
Financial Health Score (FTH)
Nexqual rates Faeth Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 05:22 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $203M cash vs $1M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$24M |
| Efficiency | Mixed — No data |
Ownership (FTH)
| Insider Ownership | +1.45% |
|---|---|
| Institutional Ownership | +25.67% |
| Shares Outstanding | 25.78M |
| Float | 1.17M |
| Short % of Float | +3.07% |
Source: Nexqual, July 25, 2026 at 05:22 UTC.
Major Backers & Investors (FTH)
Notable institutional backers of Faeth Therapeutics, Inc. include Cormorant Asset Management, LP, Millennium Management, Franklin Resources, Inc., according to Nexqual as of July 25, 2026 at 05:22 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Cormorant Asset Management, LP | 22.82% |
| Millennium Management | 10.92% |
| Franklin Resources, Inc. | 9.95% |
| Stempoint Capital LP | 9.9% |
| Caligan Partners, LP | 9.39% |
| Trails Edge Capital Partners, LP | 9.31% |
| Marshall Wace LLP | 4.9% |
| Goldman Sachs | 4.59% |
Source: Nexqual, July 25, 2026 at 05:22 UTC.
From Faeth Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-30)
Key Strengths & Strategy (as disclosed to the SEC)
- Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients.
- The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer.
- It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors.
- The company's pipeline includes SNS-102 and SNS-103, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SRZN | Surrozen, Inc. | USD 19.73 | ▼ 9.16% |
| HOWL | Werewolf Therapeutics, Inc. | USD 0.43 | ▲ 16.99% |
| TIL | Instil Bio, Inc. | USD 7.13 | ▼ 1.66% |
| VOR | Vor Biopharma Inc. | USD 19.26 | ▼ 1.28% |
| INAB | IN8bio, Inc. | USD 1.2 | ▼ 2.44% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 05:22 UTC. This page is informational and not investment advice.